In biopharma R&D and at CROs, spatial omics has become a core pillar for ๐๐ข๐จ๐ฆ๐๐ซ๐ค๐๐ซ ๐๐ข๐ฌ๐๐จ๐ฏ๐๐ซ๐ฒ, ๐ญ๐ซ๐๐ง๐ฌ๐ฅ๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐ซ๐๐ฌ๐๐๐ซ๐๐ก, ๐๐ง๐ ๐ฌ๐ฉ๐๐ญ๐ข๐๐ฅ ๐ญ๐ข๐ฌ๐ฌ๐ฎ๐ ๐ฉ๐ซ๐จ๐๐ข๐ฅ๐ข๐ง๐ ๐๐จ๐ซ ๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ ๐ฌ๐ญ๐ฎ๐๐ข๐๐ฌ. R&D teams routinely generate large numbers of high-dimensional multiplex tissue images across large cohorts, aiming to extract robust spatial biomarkers and further data that can guide drug development and patient stratification.
The challenge is no longer data generation, itโs turning complex spatial image data into ๐ฌ๐ญ๐๐ง๐๐๐ซ๐๐ข๐ณ๐๐, ๐ซ๐๐ฉ๐ซ๐จ๐๐ฎ๐๐ข๐๐ฅ๐, ๐๐ง๐ ๐๐๐๐ข๐ฌ๐ข๐จ๐ง-๐ซ๐๐๐๐ฒ ๐ข๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ ๐๐ญ ๐ฌ๐๐๐ฅ๐.
With our ๐ฌ๐ฉ๐๐ญ๐ข๐๐ฅ ๐จ๐ฆ๐ข๐๐ฌ ๐ฌ๐๐ซ๐ฏ๐ข๐๐๐ฌ and our AI-based and cloud-native ๐๐๐ญ๐๐ง๐ ๐๐๐ ๐ ๐ฉ๐ฅ๐๐ญ๐๐จ๐ซ๐ฆ, R&D teams in biopharma and at CROs can move from multiplex tissue images to standardized, decision-ready insight generations and spatial biomarker outputs ๐๐๐ฌ๐ญ, ๐ซ๐๐ฉ๐ซ๐จ๐๐ฎ๐๐ข๐๐ฅ๐, ๐๐ง๐ ๐ฌ๐๐๐ฅ๐๐๐ฅ๐.
Focus on the biology and study outcomes and let Katana Labs handle the heavy IT and analytics part.
Katana Labs ๐จ๐๐๐๐ซ๐ฌ:
๐ฏ ๐๐๐๐ฎ๐ซ๐๐ญ๐ ๐ฌ๐ข๐ง๐ ๐ฅ๐-๐๐๐ฅ๐ฅ ๐ฌ๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง for complex mIF tissues
๐ฏ ๐๐จ๐ก๐จ๐ซ๐ญ-๐ฌ๐๐๐ฅ๐ ๐ฉ๐ซ๐จ๐๐๐ฌ๐ฌ๐ข๐ง๐ across WSIs and TMAs
๐ฏ ๐๐ฎ๐๐ง๐ญ๐ข๐๐ข๐๐๐ญ๐ข๐จ๐ง ๐๐ง๐ ๐๐๐๐ญ๐ฎ๐ซ๐ ๐๐ฑ๐ญ๐ซ๐๐๐ญ๐ข๐จ๐ง at single-cell and sub-cellular resolution
๐ฏ ๐๐ฎ๐ข๐ฅ๐ญ-๐ข๐ง ๐๐/๐๐ and customized reports for confident interpretation
If you need robust spatial biomarker outputs for translational or clinical studies, contact us via Scientist.com profile or at services@katana-labs.com.
